2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley K, Parker J, Singh B, Campbell J, Ballman K, Hillman D, Winer E, El-Abed S, Piccart M, Di Cosimo S, Symmans W, Krop I, Salgado R, Loi S, Pusztai L, Perou C, Carey L, Sotiriou C. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications 2023, 14: 7053. PMID: 37923752, PMCID: PMC10624889, DOI: 10.1038/s41467-023-42635-2.Peer-Reviewed Original ResearchConceptsEvent-free survivalHER2-positive breast cancerPathological complete responseCALGB 40601Breast cancerBreast pathological complete responseStromal tumor-infiltrating lymphocytesHormone receptor statusPhase III trialsClinical nodal statusIndependent prognostic factorTumor-infiltrating lymphocytesIdentification of patientsBreast cancer prognosisT cell receptorNeoadjuvant paclitaxelNeoadjuvant therapyIII trialsNodal statusComplete responsePrognostic factorsPrognostic scoreReceptor statusClinicopathological featuresResidual disease
2011
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clinical Proteomics 2011, 8: 11. PMID: 21906370, PMCID: PMC3170272, DOI: 10.1186/1559-0275-8-11.Peer-Reviewed Original ResearchRecurrence-free survivalPathological complete responseBreast cancerComplete responseBiomarker panelDifferent recurrence-free survivalPathologic complete responseCohort of patientsPrimary breast cancerManagement of patientsBreast cancer subgroupsSurgical excision specimensProbability of recurrenceNeoadjuvant taxaneSystemic therapyPrognostic scorePrognostic groupsPrognosis scoreOrdinal logistic regressionCancer subgroupsExcision specimensPatientsFNA biopsySignificant associationPhase protein array
2010
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers. Journal Of Clinical Oncology 2010, 28: 4316-4323. PMID: 20805453, DOI: 10.1200/jco.2009.27.2419.Peer-Reviewed Original ResearchMeSH KeywordsAmyloid beta-Protein PrecursorAntineoplastic Agents, HormonalBiopsy, Fine-NeedleB-LymphocytesBreast NeoplasmsChi-Square DistributionCollagen Type IVExtracellular Matrix ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMetagenomeNeoplasm Recurrence, LocalPhospholipid Transfer ProteinsPrognosisProportional Hazards ModelsProspective StudiesProtease NexinsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Cell SurfaceReceptors, EstrogenReceptors, Transforming Growth Factor betaSurvival AnalysisTamoxifenConceptsER-negative cancersBreast cancer stromaER-positive cancersPrognostic valueCancer stromaNegative cancersProliferative cancersSystemic adjuvant therapyTamoxifen-treated patientsNode-negative patientsEstrogen-receptor positiveStrong prognostic valueCore needle biopsySubset of tumorsLess prognostic valueDistant relapseAdjuvant therapyHazard ratioFavorable prognosisHighest tertilePrognostic scoreCore biopsyBreast cancerImmune functionMultivariate analysis